Histotripsy Liver Tumor Programs to Begin at Leading Hong Kong Universities
HistoSonics, a leading innovator in medical technology, has announced a major partnership with the Li Ka Shing Foundation to introduce its advanced liver tumor treatment technology to Hong Kong. This collaboration is set to transform the treatment landscape for liver cancer in the region. The Foundation, spearheaded by renowned philanthropist Li Ka-shing, has generously funded the acquisition of two Edison™ Histotripsy Systems, marking a significant milestone for both organizations.
The donated systems will be installed at two prominent Hong Kong institutions: the University of Hong Kong and the Chinese University of Hong Kong. The University of Hong Kong will be the first to receive its histotripsy system, while the Chinese University of Hong Kong is scheduled to receive its system early next year. This initiative represents the inaugural deployment of histotripsy technology in Asia.
Revolutionary Treatment for Liver Tumors
Histotripsy is a groundbreaking technique that utilises focused ultrasound to treat liver tumors. The technology operates by emitting high-amplitude, short pulses to create a “bubble cloud” within the tumor. This cloud of microbubbles forms and collapses rapidly, generating mechanical forces that break down the tumor tissue into a liquefied state without the need for invasive procedures. This non-invasive method offers significant advantages over traditional treatments, such as reduced risk of surgical site infections, less bleeding, and minimal radiation exposure.
Mr. Li Ka-shing, a prominent advocate for medical innovation, remarked, “The use of the HistoSonics Histotripsy System, which involves forming microbubbles to destroy tumors, is truly fascinating. I am confident that such advancements in medical technology will bring both hope and new opportunities to the people of Hong Kong.”
Training and Implementation
Healthcare professionals from both the University of Hong Kong and the Chinese University of Hong Kong recently underwent intensive training at HistoSonics’ headquarters in Minneapolis. This training ensures that the staff are well-equipped to use the histotripsy systems effectively and to deliver high-quality patient care. The hospitals are anticipated to commence patient treatments using histotripsy as soon as this week.
Mike Blue, CEO and President of HistoSonics, expressed his enthusiasm for the partnership, stating, “We are incredibly excited to work with these esteemed universities and to bring our innovative therapy to Hong Kong. With Asia hosting a substantial proportion of the global population affected by liver diseases, we believe our histotripsy technology will have a profound impact on improving patient outcomes. We extend our sincere gratitude to the Li Ka Shing Foundation and Mr. Li for their visionary support.”
Future Research and Clinical Programs
Both Hong Kong-based hospitals will participate in HistoSonics’ BOOMBOX study, a comprehensive clinical program aimed at gathering data on the application of histotripsy for various liver tumor types and stages. This study will provide valuable insights into the effectiveness and safety of the technology, supporting its broader adoption.
The Edison Histotripsy System is specifically designed for the non-invasive destruction of liver tumors, including those that are considered unresectable. By employing a mechanical, non-thermal approach, the system aims to offer a safer, more effective treatment option for patients.